Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00794716
Recruitment Status : Completed
First Posted : November 20, 2008
Last Update Posted : June 10, 2015
Information provided by (Responsible Party):

Brief Summary:
This study is to evaluate the predictive value of NRL972 pharmacokinetics in the diagnosis of steatohepatitis using fatty liver disease as the comparator group. In addition, the sensitivity and specificity of NRL972 pharmacokinetics as a diagnostic tool will be compared to results from the standard laboratory tests, elastography, tests of metabolic markers and serum fibrosis markers frequently used in the evaluation of clinically predicted NAFLD patients. Patients will be included if they have clinical evidence of fatty liver disease and have been referred to the clinic for a diagnostic work-up, including a liver biopsy, blood tests and scans of the liver.

Condition or disease Intervention/treatment Phase
Non-Alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis Drug: NRL972 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 125 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients With Clinical Evidence for Non-alcoholic Fatty Liver Disease (NAFLD): Supporting the Disease Staging Into Fatty Liver Disease Versus Non-alcoholic Steatohepatitis (NASH)
Study Start Date : June 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : November 2011

Arm Intervention/treatment
Experimental: NRL972 Drug: NRL972
Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.

Primary Outcome Measures :
  1. The primary efficacy variable is the NRL972 fractional retention ratio for 10 and 30 minutes post-dose (C30/C10) for different populations with NAFLD. [ Time Frame: 30 minutes post-dose ]

Secondary Outcome Measures :
  1. Approximate overall clearance and t½ within 60 minutes of dosing with NRL972. Cmax, AUC(0-∞), and mean residence time derived from a non-compartmental analysis. [ Time Frame: 60 minutes post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects meeting the following conditions will be eligible for enrollment:

  • Males or females (females of non-child-bearing potential or of child-bearing potential while taking medically appropriate contraception)
  • Any ethnicity
  • Age: 18 to 80 years of age
  • Clinical evidence of non-alcoholic liver disease requiring the conduct of a liver biopsy for the diagnosis of NAFLD and/or staging of disease severity
  • Willing and able to provide informed consent

Exclusion Criteria:

Subjects fulfilling any of the following criteria will be excluded from enrollment:

General - all subjects

  • Presence of acute or chronic viral hepatitis confirmed by serology
  • Clinical signs of significant cholestasis
  • Liver impairment due to space-occupying processes (e.g. carcinoma)
  • Liver transplant recipient or patient scheduled for liver transplantation
  • Clinically evident rapidly deteriorating hepatic function
  • Significant bleeding diathesis
  • Esophageal bleeding within the 8 weeks prior to study entry
  • Presence of any contraindications for the conduct of the planned liver biopsy (e.g. allergy to lidocaine, coagulopathy with <100 x109/L thrombocytes and/or INR >1.3
  • History of any allergic reaction to fluorescein
  • Presence of any acute infection
  • Previous participation in this trial
  • Having received any investigational drug or treatment within 30 days prior to study entry or requiring a concurrent treatment with any other experimental drug or treatment
  • Uncontrolled hypo- or hypertension (treated or untreated) with resting systolic blood pressure >160 or < 90 mmHg, diastolic blood pressure >95 or < 50 mmHg
  • Clinically relevant abnormal laboratory values indicating end-stage renal, pulmonary or cardiac disease
  • Known HIV infection
  • Concurrent alcohol use of more than 14 drinks (140g ethanol) for men and 7 drinks (70g ethanol) for women per week (each drink is counted as 10g ethanol)
  • History of drug or alcohol abuse within 2 months prior to dosing
  • Use of prohibited medication (section 4.8)
  • Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months
  • Suspicion or evidence that the subject is not trustworthy and reliable
  • Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard
  • Significant side effects prior to the liver biopsy (e.g. anxiety requiring pre-medication) or after the biopsy (e.g. pain requiring i.v. pain medication, bleeding re-quiring medical intervention)

General - all females

  • Positive pregnancy test
  • Pre-menopausal women not using appropriate contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00794716

Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Manal F Abdelmalek, M.D., MPH Duke University

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Norgine Identifier: NCT00794716    
Other Study ID Numbers: NRL972-01/2007 (FLD)
First Posted: November 20, 2008    Key Record Dates
Last Update Posted: June 10, 2015
Last Verified: August 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases